Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL
April 01, 2021 08:45 ET
|
Autolus Therapeutics plc
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Updated Manufacturing Facility Strategy Leveraging its UK Operations
March 29, 2021 08:00 ET
|
Autolus Therapeutics plc
- Autolus to expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy- Mutual agreement to terminate lease for...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
March 04, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
February 24, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
February 12, 2021 16:01 ET
|
Autolus Therapeutics plc
LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Pricing of Public Offering
February 09, 2021 20:42 ET
|
Autolus Therapeutics plc
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
February 08, 2021 16:19 ET
|
Autolus Therapeutics plc
LONDON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 4
February 04, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics provides business outlook for 2021 & 2022
January 06, 2021 04:07 ET
|
Autolus Therapeutics plc
• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022• Company intends to partner...
Autolus Therapeutics to participate in Investor Conferences through January
January 04, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...